Sonata vs. Quviviq

See how Sonata and Quviviq compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Sonata is a short-acting sedative-hypnotic approved only for short-term insomnia, while Quviviq is a newer orexin blocker with no defined treatment-duration limit on its label.

  • Both carry warnings for complex sleep behaviors and are Schedule IV controlled substances, but Sonata is available as a much less expensive generic.

  • Sonata's very short half-life makes it useful for falling back asleep in the middle of the night, while Quviviq targets both sleep onset and sleep maintenance.

Sonata vs. Quviviq Drug Summary

Sonata

Sonata (zaleplon) is a nonbenzodiazepine sedative-hypnotic that treats short-term insomnia in adults. It comes as an oral capsule taken once nightly at bedtime, or in the middle of the night if at least four hours of sleep time remain. Its very short half-life helps limit next-day grogginess when dosed correctly.

Quviviq

Quviviq (daridorexant) is a dual orexin receptor antagonist that treats insomnia involving trouble falling asleep, staying asleep, or both. It is taken as a single oral tablet once nightly, close to bedtime, with several hours planned before waking. As a newer class of sleep medication, it works by blocking wake-promoting orexin signals rather than sedating the brain broadly.

Sonata vs. Quviviq Side Effects

Sonata

Most common
headache (up to 28%)
somnolence (up to 5%)
nausea (up to 7%)
dizziness (up to 7%)

Quviviq

Most common
headache (up to 6.5%)
somnolence (5% to 7%)
nasopharyngitis (up to 9.0%)
fatigue (5% to 7%)

Sonata vs. Quviviq Dosage

Sonata

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 5 mg once nightly At the start
Maximum dose 20 mg once nightly If needed
Dose changes 2 increases As tolerated

Quviviq

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 25 mg once nightly At the start
Maximum dose 50 mg once nightly If needed
Dose changes 1 increase As tolerated

Sonata vs. Quviviq Indications

Sonata

Sonata is FDA-approved only for the short-term treatment of insomnia in adults, not for ongoing nightly use. It is not approved for anyone under 18. Doctors often prescribe it for people who need occasional help falling asleep or who wake in the night and need to fall back asleep quickly.

  • Short-term insomnia in adults only

  • Can be dosed mid-night if 4+ hours sleep remain

  • Not approved for chronic nightly use

  • Not approved for patients under 18

Quviviq

Quviviq is FDA-approved for insomnia in adults who have trouble falling asleep, staying asleep, or both. Unlike Sonata, its label does not restrict use to short-term treatment. It is not approved for narcolepsy and is contraindicated in people with that condition.

  • Insomnia with sleep-onset or maintenance issues

  • No short-term use restriction on the label

  • Not approved for narcolepsy

  • Contraindicated in narcolepsy patients

Sonata vs. Quviviq Pros and Cons

Sonata

Sonata's ultra-short half-life and non-CYP metabolism give it a distinct niche among hypnotics: fast onset, quick clearance, and few drug interactions. It's only approved for short-term use, and long-term nightly reliance falls outside its label. Generic pricing makes it one of the most affordable prescription sleep aids available.

Pros

  • Very short half-life may limit next-day grogginess

  • Can be taken mid-night if 4+ hours sleep remain

  • Metabolized without CYP enzymes, fewer interactions

  • Roughly $25 to $115 per month as a generic

Cons

  • Only approved for short-term insomnia treatment

  • Contains FD&C Yellow No. 5, a possible allergen

  • Needs lower dose in elderly or hepatic impaired

Quviviq

Quviviq offers a newer mechanism, blocking orexin signals instead of broadly sedating the brain, and its label does not limit use to short-term treatment. It requires no dose adjustment for kidney problems, though liver dosing needs care. Its list price is substantially higher than generic zaleplon.

Pros

  • No short-term use restriction on the label

  • No dose adjustment needed for kidney problems

  • No signs of physical dependence in trials

  • Newer orexin-blocking mechanism, an alternative option

Cons

  • Contraindicated in people with narcolepsy

  • Risk of worsening depression or suicidal thoughts

  • Roughly $520 to $685 per month, no generic yet

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.